Intrinsic Value of S&P & Nasdaq Contact Us

Genelux Corporation GNLX NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
43/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$17.33
+510.2%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Genelux Corporation (GNLX) has a negative trailing P/E of -2.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 4.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -34.42%, forward earnings yield 21.23%. PEG 0.03 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

  • VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.03); analyst target implies upside (+510.2%).
  • Forward P/E 4.7 — analysts expect a return to profitability with estimated EPS of $0.60 for FY2029.
  • PEG Ratio 0.03 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield -34.42% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 21.23% as earnings recover.
  • Analyst consensus target $17.33 (+510.2% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 43/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score
43/100
SG Score
View full scorecard →
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
FUTURE
73/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
MOAT
0/100
→ Income
GROWTH
15/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — GNLX

Valuation Multiples
P/E (TTM)-2.9
Forward P/E4.7
PEG Ratio0.03
Forward PEG0.03
P/B Ratio8.09
P/S Ratio11,811.71
EV/EBITDA-2.8
Per Share Data
EPS (TTM)$-0.86
Forward EPS (Est.)$0.60
Book Value / Share$0.31
Revenue / Share$0.00
FCF / Share$-0.71
Yields & Fair Value
Earnings Yield-34.42%
Forward Earnings Yield21.23%
Dividend Yield0.00%
Analyst Target$17.33 (+510.2%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2019 -12.5 0.00 -5.85 0.00 -
2020 -9.8 -0.53 -6.41 0.00 -
2021 -8.2 -0.43 -4.39 0.00 -
2022 -29.0 0.42 -4.22 13.64 -
2023 -12.1 -0.03 17.58 2,013.26 -
2024 -2.5 0.14 2.82 9,277.96 -
2025 -5.0 0.53 14.04 20,261.21 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2019 $-0.49 $0.00 $-11.63M -
2020 $-0.63 $0.00 $-14.86M -
2021 $-0.75 $0.00 $-17.8M -
2022 $-0.21 $11.07M $-5.21M -47%
2023 $-1.16 $170K $-28.3M -16645.3%
2024 $-0.95 $8K $-29.87M -373362.5%
2025 $-0.86 $8K $-32.15M -401812.5%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $-0.82 $-0.88 – $-0.76 $2.65M $2.65M – $2.65M 4
2027 $-0.82 $-0.82 – $-0.82 $15.27M $15.27M – $15.27M 3
2028 $-0.21 $-0.98 – $0.63 $87.71M $87.71M – $87.71M 4
2029 $0.60 $0.60 – $0.60 $188.14M $188.14M – $188.14M 2
2030 $1.45 $1.45 – $1.45 $296.18M $296.18M – $296.18M 2
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message